Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89%
PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR.
Pfizer & The MPP Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access
Agreement builds on Pfizer’s comprehensive strategy to work toward equitable access to COVID-19 vaccines and treatments for all people.
Drones Ferry Pfizer’s Precious, Deep Frozen Vaccine to Africa’s Remote Villages
Tens of thousands of shots will be carried to the ‘real last mile’ as part of Covax program to improve global distribution.